Cholest-5-en-3-yl palmitate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Cholest-5-en-3-yl palmitate
• 英文别名: [(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hexadecanoate
• 化学式: C₄₃H₇₆O₂
• 分子量: 625.1
• InChiKey: BBJQPKLGPMQWBU-FPGZLIPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.4
• 重原子数：
  45
• 可旋转键数：
  21
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Targeted delivery of imaging probes for in vivo cellular imaging
  申请人：Kao Joseph P. Y.

  公开号：US10202342B2

  公开（公告）日：2019-02-12

  The present invention relates to nitroxide imaging probes that are isotopically modified or unmodified. Such nitroxide imaging probes may be included in liposomes that encapsulate self-quenching concentrations thereof, wherein the liposomes optionally comprise a targeting ligand specific to and having affinity for targeted tissue.

  本发明涉及的是同位素改性的或未改性的硝基氧成像探针。这样的硝基氧成像探针可以包含在封装了自猝灭浓度硝基氧的脂质体中，其中脂质体可选地包含一种针对目标组织具有特异性和亲和力的靶向配体。
• HETEROMULTIVALENT NANOPARTICLE COMPOSITIONS
  申请人：Case Western Reserve University

  公开号：US20140023591A1

  公开（公告）日：2014-01-23

  A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.

  用于诊断和治疗应用的组合物包括具有外表面的异多价纳米粒子，其表面上结合有多个靶向基团，这些靶向基团包括第一活化的血小板靶向基团和第二活化的血小板靶向基团。
• [EN] VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE CHOLESTÉROL VASCULAIRE ET LEUR UTILISATION
  申请人：IPROTEOS S L

  公开号：WO2020225245A1

  公开（公告）日：2020-11-12

  The present invention relates to compounds having pharmacological activity in the treatment of vascular cholesterol accumulation, plasma low-density lipoproteins (LDL) abnormal aggregation and/or inhibition or reduction of the formation of VSMC foam cells, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and/or prophylaxis of conditions wherein decrease of vascular cholesterol accumulation, inhibition of LDL aggregation, inhibition or reduction of the formation of VSMC foam cells and/or prevention of aggregated LDL (agLDL) internalization is useful such as atherosclerosis, coronary artery disease, stroke, peripheral artery disease, angina pectoris, thrombosis, hyperlipidemia, hyperlipoproteinemia type II, familial hypercholesterolemia, familial combined hyperlipidemia, type II diabetes, hypothyroidism, Cushing's syndrome and obesity.

  本发明涉及具有药理活性的化合物，用于治疗血管内胆固醇积聚、血浆低密度脂蛋白（LDL）异常聚集和/或抑制或减少VSMC泡沫细胞形成的过程，以及它们的制备方法、包含它们的药物组合物，以及它们在治疗和/或预防血管内胆固醇积聚减少、LDL聚集抑制、VSMC泡沫细胞形成抑制或减少和/或预防聚集的LDL（agLDL）内化等疾病症状的治疗中的用途，如动脉粥样硬化、冠状动脉疾病、中风、外周动脉疾病、心绞痛、血栓形成、高脂血症、高脂蛋白血症II型、家族性高胆固醇血症、家族性混合性高脂蛋白血症、II型糖尿病、甲状腺功能减退症、库欣综合征和肥胖症。
• Compounds for targeting endothelial cells, compositions containing the same and methods for their use
  申请人：——

  公开号：US20020147136A1

  公开（公告）日：2002-10-10

  The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

  本发明提供了用于靶向内皮细胞、肿瘤细胞或其他表达NP-1受体的细胞的化合物，包含这些化合物的组合物以及它们的使用方法。此外，本发明还包括用于可视化、治疗或放射治疗的诊断、治疗和放射治疗组合物。
• 1,3,5-Triazines for Treatment of Viral Diseases
  申请人：Daifuku Richard

  公开号：US20070207973A1

  公开（公告）日：2007-09-06

  The present invention provides compounds and methods for treatment of viral diseases and cancer.

  本发明提供了用于治疗病毒性疾病和癌症的化合物和方法。